All articles tagged with #car t
The NHS has funded and begun delivering CAR-T cell therapy for adults with B‑cell ALL, with 28‑year‑old Oscar Murphy receiving the first infusion in Manchester. The personalised “living drug” reprograms a patient’s T‑cells to attack cancer and could extend survival; trial data showed 77% remission and about 15.6 months of added life, with around 50 patients a year expected to benefit across the UK.
Bristol Myers Squibb has acquired Orbital Therapeutics for $1.5 billion to expand its involvement in cell therapies, particularly CAR-T treatments.
A new CAR-T immunotherapy developed by Legend Biotech and marketed by Johnson & Johnson has shown promising results in treating advanced multiple myeloma, with about a third of patients experiencing long-term remission, prompting discussions of a potential cure for this previously incurable blood cancer.
Chinese scientists have developed a pioneering CAR-T cell therapy that offers the potential for a one-time treatment for asthma, a condition that currently requires lifelong management. This therapy, which targets key cytokines driving asthma, has shown promising results in animal studies, providing long-term relief from symptoms. While the findings are encouraging, experts stress the need for further research to ensure the therapy's safety and efficacy in humans.
The US FDA has requested a "boxed warning" to be added to the prescribing information for CAR-T cancer therapies, including those made by Gilead Sciences, Johnson & Johnson, Novartis, and others, due to reports of patients developing T-cell blood cancer after treatment. Novartis has agreed to update the prescribing information for its CAR-T cell therapy Kymriah, while Bristol Myers is evaluating next steps for its therapies. The FDA has identified adverse events and clinical trial reports describing T-cell malignancies and considers the risks applicable to all therapies in the category.
Allogene Therapeutics is altering its development strategy for ALLO-501A, an off-the-shelf cell therapy for blood cancer, due to intense competition from personalized CAR-T treatments. The company is discontinuing two ongoing clinical trials for patients with advanced-stage lymphoma and instead will initiate a new study targeting newly diagnosed high-risk lymphoma patients. This shift aims to position ALLO-501A more effectively in the competitive blood cancer treatment landscape.
Prime Medicine is considering developing cell therapies for autoimmune diseases and may seek a partner for cancer cell therapies. The biotech would join a growing list of groups creating CAR-T therapies for autoimmune conditions like lupus, which were first developed for cancer and have been transformative for patients who can access them.
Hadassah-University Medical Center in Jerusalem has developed a groundbreaking treatment for multiple myeloma cancer using genetic engineering technology called CAR-T, which boosts the patient’s own immune system to destroy the cancer. Over 90% of the 74 patients treated at Hadassah went into complete remission. The treatment is still being conducted as an experiment, with a waiting list of over 200 patients from Israel and various parts of the world. The experimental treatment will also be provided throughout the US in the coming months.
Johnson & Johnson's CAR-T therapy, Carvykti, developed in partnership with Legend Biotech, has shown a 74% reduction in the risk of multiple myeloma progression or death, according to leaked abstract data. The results could put Carvykti ahead of competitor Abecma, developed by Bristol Myers Squibb and 2seventy bio, in earlier lines of treatment if and when it's approved for those indications. The study's results surprised analysts, with a Cowen analyst describing it as "game-changing efficacy," and sent Legend's shares 14% higher after Wednesday's opening bell.